Evidence map›Paper›PMID 34327631›Full record

ArticleImmunologic research2021

AKAP12/Gravin is over-expressed in patients with ulcerative colitis.

Gabriela Fonseca-Camarillo, Janette Furuzawa-Carballeda, Ángel Alexis Priego-Ranero, Rafael Barreto Zúñiga, Braulio Martínez-Benítez, Jesús K Yamamoto-Furusho

Abstract read
PubMed Publisher
In one paragraph

Article in Immunologic research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Gabriela Fonseca-CamarilloInflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicasy Nutrición Salvador Zubirán, Vasco de Quiroga #15, Col. Belisario Domínguez Sección XVI, CP, CDMX, 14080, Mexico City, Mexico.ORCID 0000-0002-7489-2596
Janette Furuzawa-CarballedaDepartment of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0001-5804-7221
Ángel Alexis Priego-RaneroDepartment of Internal Medicine, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0002-7801-6438
Rafael Barreto ZúñigaDepartment of Endoscopy, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico.
Braulio Martínez-BenítezDepartment of Pathology, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico.ORCID 0000-0002-8925-8651
Jesús K Yamamoto-FurushoInflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicasy Nutrición Salvador Zubirán, Vasco de Quiroga #15, Col. Belisario Domínguez Sección XVI, CP, CDMX, 14080, Mexico City, Mexico. kazuofurusho@hotmail.com.ORCID 0000-0002-5247-5812
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The gene of A-kinase anchor protein 12 (AKAP12) regulates cell cycle progression, cell motility, and morphology through its multiple scaffolding domains. However, the role of AKAP12 expression in ulcerative colitis (UC) patients has not been yet described. The aim of the study was to describe the gene and protein of AKAP12 expression in patients with UC and its association regarding the disease severity. We included a total of 40 patients with confirmed diagnosis of UC and 25 controls without endoscopic evidence of colitis or neoplasia. The relative quantification of the gene expression was performed by real-time PCR for AKAP12. Kruskal-Wallis was used to test differences among groups, and Spearman correlation to assess the relationship between AKAP12 gene and clinical outcomes. The extent of disease was evaluated using total colonoscopy, and biopsies were taken from rectum segments. The AKAP12 gene expression was increased in colonic mucosa from patients with active UC when compared with UC remission and control group. The overexpression of AKAP12 in patients with UC was associated with the presence of extensive colitis (p = 0.04, RM = 12, IC = 1.29-186.37). AKAP12/CD16 double positive cells were higher in submucosa (p = 0.04), muscular (p < 0.001), and cells from serosa (p < 0.001) in patients affected by UC in comparison to controls. The overexpression of AKAP12 was associated with the extent of disease. This is the first report about the role of AKAP12 in patients with UC suggesting that this gene and its protein could be involved in the modulation of the disease.

Indexed as

Gene ExpressionA Kinase Anchor ProteinsBiomarkersBiopsyCase-Control StudiesCell Cycle ProteinsColitis, UlcerativeColonoscopyDisease ManagementDisease SusceptibilityFemaleGene Expression ProfilingHumansImmunohistochemistryIntestinal MucosaMaleAKAP12 protein, humanA Kinase Anchor ProteinsBiomarkersCell Cycle ProteinsAKAP12/GRAVINExtensive colitisInflammationUlcerative colitis

Identifiers

PMID34327631
OpenAlexW3184900238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.